MetaCap

BriaCell Therapeutics (BCTX) vs Rein Therapeutics (RNTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BriaCell Therapeutics (BCTX) has outperformed Rein Therapeutics (RNTX) over the past year, losing 61.7% versus a loss of 77.2%. Over five years, BCTX leads with a -97.0% price change compared with -97.5% for RNTX. Rein Therapeutics is the larger company by market cap ($29.1 million vs $26.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BCTX-61.75%RNTX-77.24%
+65%-10%-84%
Nov 21, 20251 yearNov 20, 2026
BCTX-97.12%RNTX-97.57%
+18%-43%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BCTX versus RNTX key metrics
MetricBCTXRNTX
Share price$3.06$0.3369
Market cap$26.72M$29.06M
1-day change-3.32%-8.38%
YTD return-56.96%-70.96%
1-year return-61.75%-77.24%
5-year return-97.00%-97.47%
EPS (TTM)$-6.97$-1.51
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Net income (latest FY)$-34.90M$-49.87M
52-week high$13.09$2.10
52-week low$2.60$0.284
Distance from 52-week high-76.62%-83.96%
Analyst consensus—none
Avg. price target upside—+1680.94%
Average volume250.81K586.68K
Shares outstanding8.73M86.27M
Employees—10
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BCTX has outperformed RNTX by 15.5 percentage points over the past year.

About BriaCell Therapeutics

BCTX stock →

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.

Health Care · Biotechnology: Pharmaceutical Preparations

About Rein Therapeutics

RNTX stock →

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

BCTX vs RNTX FAQ

Which is bigger, BriaCell Therapeutics or Rein Therapeutics?

Rein Therapeutics (RNTX) is larger, with a market capitalization of $29.06M compared with $26.72M for BriaCell Therapeutics (BCTX).

Which stock has performed better over the past year, BCTX or RNTX?

BCTX returned -61.75% over the past 12 months, compared with -77.24% for RNTX (price return, excluding dividends). Past performance does not predict future results.

Are BriaCell Therapeutics and Rein Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons